Press Releases

Distributed: Feb 19, 2009

Alerts Login

Melbourne, Feb 19, 2009 (ABN Newswire) - Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) Net loss after tax was A$1.9 million, with operating cash outflows of A$2.5 million for the half year, 12% less than the same period in the prior year. Cash at 31 December was A$6.1 million. Total revenue and other income was A$5.1 million for the half year with revenue from continuing operations A$1.0 million for the six months, up 6% compared with the same period in the prior year.

Receipts from customers included royalty and license income from partners including SSL International and Dade Behring (part of the Siemens Healthcare group), and grant and contract payments from the U.S. National Institutes of Health for VivaGel(R) development costs. The receipts from SSL International represent the first payment under the strategically important partnership with SSL International for the VivaGel(R) coated condom, which Starpharma has estimated will yield total receipts in excess of A$100m.

Apart from the VivaGel(R) coated condom and stand-alone products, the Company is continuing to focus on near-term commercial partnerships in areas such as drug delivery, cosmetics / personal care products and diagnostics.


About Starpharma Holdings Limited

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

Contact

Dr Jackie Fairley
Chief Executive Officer
TEL: +61-3-8532-2704

Ben Rogers
Company Secretary
TEL: +61-3-8532-2702
ben.rogers@starpharma.com


  Related Companies

>>>        Starpharma Holdings Limited

  Related Industry Topics:

Biotech | Drugs & OTC | Financial General | Health & Pharm General | 

  This Page Viewed:  (Last 7 Days: 50) (Last 30 Days: 300) (Since Published: 19860) 

Events & Exhibitions

Site Search

 
 ENGLISH   All Languages
Webcast Your Annual General Meeting

ABN Newswire on iPhone/iPad

Download from Apple

Mobile Video TV

qrcode
Scan with your Mobile Phone to view ABN Newswire Video Channel on Mobile
 
City Index - A Better Way To Trade